ADC Therapeutics SA Files Q1 2025 10-Q Report
Ticker: ADCT · Form: 10-Q · Filed: May 14, 2025 · CIK: 1771910
| Field | Detail |
|---|---|
| Company | Adc Therapeutics SA (ADCT) |
| Form Type | 10-Q |
| Filed Date | May 14, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-Q, financials, pharmaceutical
TL;DR
ADC Therapeutics SA filed its Q1 2025 10-Q. Financials and operations detailed.
AI Summary
ADC Therapeutics SA filed its 10-Q for the period ending March 31, 2025. The filing details financial performance and operational updates for the first quarter of 2025. Key financial figures and business developments are presented within this report.
Why It Matters
This filing provides investors with a quarterly update on ADC Therapeutics SA's financial health and business progress, crucial for investment decisions.
Risk Assessment
Risk Level: medium — As a pharmaceutical company, ADC Therapeutics SA faces inherent risks related to drug development, regulatory approvals, and market competition.
Key Players & Entities
- ADC Therapeutics SA (company) — Filer of the 10-Q report
- 20250331 (date) — Conformed period of report
- 20250514 (date) — Filed as of date
- 0001771910 (company) — Central Index Key for ADC Therapeutics SA
FAQ
What is the reporting period for this 10-Q filing?
The conformed period of report is March 31, 2025.
When was this 10-Q filing submitted?
The filing was submitted on May 14, 2025.
What is the Standard Industrial Classification for ADC Therapeutics SA?
The SIC code is Pharmaceutical Preparations [2834].
Where is ADC Therapeutics SA's business address?
The business address is Biopole, Route de la Corniche 3B, Epalinges, 1066.
What is the fiscal year end for ADC Therapeutics SA?
The fiscal year ends on December 31.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on May 14, 2025 regarding ADC Therapeutics SA (ADCT).